Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06533579
What this trial is testing

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc. 32
Early research (Phase 1)Study completedNCT00002818
What this trial is testing

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

Who this might be right for
Drug/Agent Toxicity by Tissue/OrganLeukemiaLymphoma+1 more
Virginia Commonwealth University 15
Testing effectiveness (Phase 2)Ended earlyNCT00079443
What this trial is testing

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
National Cancer Institute (NCI) 60
Early research (Phase 1)Looking for participantsNCT05963217
What this trial is testing

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Who this might be right for
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto 19
Early research (Phase 1)Study completedNCT00060684
What this trial is testing

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Low-GradeLymphoma, Small LymphocyticLymphoma, Mixed-Cell, Follicular+1 more
CTI BioPharma 30
Early research (Phase 1)Study completedNCT01429025
What this trial is testing

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology 26
Large-scale testing (Phase 3)WithdrawnNCT06205290
What this trial is testing

Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Testing effectiveness (Phase 2)Study completedNCT01177371
What this trial is testing

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+70 more
Case Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)Ended earlyNCT01119794
What this trial is testing

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

Who this might be right for
Lymphoma, Non-Hodgkins
Brown University 10
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Early research (Phase 1)Study completedNCT03003546
What this trial is testing

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic Lymphoma+3 more
Mayo Clinic 9
Testing effectiveness (Phase 2)WithdrawnNCT05365100
What this trial is testing

BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

Who this might be right for
CLL/SLLNHL
BioNova Pharmaceuticals (Shanghai) LTD.
Testing effectiveness (Phase 2)Ended earlyNCT00625729
What this trial is testing

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Masonic Cancer Center, University of Minnesota 6
Testing effectiveness (Phase 2)Study completedNCT00022581
What this trial is testing

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma+1 more
National Cancer Institute (NCI) 45
Early research (Phase 1)Study completedNCT00513474
What this trial is testing

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more
Massachusetts General Hospital 46
Early research (Phase 1)Ended earlyNCT02109224
What this trial is testing

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaCutaneous B-Cell Non-Hodgkin Lymphoma+26 more
National Cancer Institute (NCI) 72
Early research (Phase 1)Looking for participantsNCT06191887
What this trial is testing

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more
Mayo Clinic 27
Not applicableStudy completedNCT00098566
What this trial is testing

Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaQuality of Life
Fred Hutchinson Cancer Center 36
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Next Page